General Pharmacokinetic Model for Drugs Exhibiting Target-Mediated Drug Disposition
The DOI matches its Crossref record; 40 of the 40 references it cites were found in a registry or an index.
Abstract
Drugs that bind with high affinity and to a significant extent (relative to dose) to a pharmacologic target such as an enzyme, receptor, or transporter may exhibit nonlinear pharmacokinetic (PK) behavior. Processes such as receptor-mediated endocytosis may result in drug elimination. A general PK model for characterizing such behavior is described and explored through computer simulations and applications to several therapeutic agents. Simulations show that model predicted plasma concentration vs. time profiles are expected to be polyexponential with steeper distribution phases for lower doses and similar terminal disposition phases. Noncompartmental parameters always show apparent Vss and CL(D) decreasing with dose, but apparent clearance decreases only when the binding process produces drug elimination. The proposed model well captured the time-course of drug concentrations for the aldose reductase inhibitor imirestat, the endothelin receptor antagonist bosentan, and recombinant human interferon-beta 1a. This type of model has a mechanistic basis and considerable utility for fully describing the kinetics for various doses of relevant drugs.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“More importantly, target-mediated drug disposition (TMDD) introduces a saturable, dose- and concentration-dependent component of clearance that no power-law regression can capture.”
From Beyond Body Weight: A Comprehensive Review of Allometric Scaling in Drug Development for Human Dose Predictions (2026) · cites this paper as [50]
In the citing paper
“At low concentrations, target-mediated clearance can dominate; at high concentrations, the target is saturated and linear, FcRn-mediated elimination dominates [47,50].”
From Beyond Body Weight: A Comprehensive Review of Allometric Scaling in Drug Development for Human Dose Predictions (2026) · cites this paper as [50]
In the citing paper
“A practical constraint in biologics first-in-human modelling is that not all of these disposition parameters can be identified simultaneously. FcRn-mediated linear clearance and central volume of distribution generally scale reliably from non-human primate data and can be estimated with reasonable confidence, whereas TMDD parameters such as target baseline concentration, target turnover, and”
From Beyond Body Weight: A Comprehensive Review of Allometric Scaling in Drug Development for Human Dose Predictions (2026) · cites this paper as [50]
In the citing paper
“For biologics in particular, this also recognizes that not all parameters are simultaneously identifiable: FcRn-mediated linear clearance and central volume can be carried from non-human primate data, whereas poorly identifiable TMDD parameters are fixed to in vitro or literature values rather than estimated [50,51] (Section 4.5).”
From Beyond Body Weight: A Comprehensive Review of Allometric Scaling in Drug Development for Human Dose Predictions (2026) · cites this paper as [50]
Citations
Cites
Gibaldi, M., & Perrier, D. (1982) · CRC Press eBooks · doi:10.1201/b14095 · Cited by 4,093
Noseworthy, J. H., Lucchinetti, C., Rodriguez, M., & Weinshenker, B. G. (2000) · New England Journal of Medicine · doi:10.1056/nejm200009283431307 · Cited by 2,899
Pestka, S., Langer, J. A., Zoon, K. C., & Samuel, C. E. (1987) · Annual Review of Biochemistry · doi:10.1146/annurev.bi.56.070187.003455 · Cited by 1,825
Protein Sorting by Transport Vesicles
Rothman, J. E., & Wieland, F. T. (1996) · Science · doi:10.1126/science.272.5259.227 · Cited by 1,153
Operational models of pharmacological agonism
Black, J. W., & Leff, P. (1983) · Proceedings of the Royal Society of London. Series B. Biological Sciences · doi:10.1098/rspb.1983.0093 · Cited by 951
Comparison of four basic models of indirect pharmacodynamic responses
Dayneka, N. L., Garg, V., & Jusko, W. J. (1993) · Journal of Pharmacokinetics and Biopharmaceutics · doi:10.1007/bf01061691 · Cited by 821
Self-citationClozel, M., Breu, V, Gray, G. A., Kalina, B., Löffler, B. M., Burri, K., Cassal, J. M., Hirth, G., Müller, M., & Neidhart, W. (1994) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(25)22357-6 · Cited by 661
Recycling receptors: the round-trip itinerary of migrant membrane proteins
Brown, M. S., Anderson, R. G. W., & Goldstein, J. L. (1983) · Cell · doi:10.1016/0092-8674(83)90052-1 · Cited by 587
Gianni, L., Kearns, C. M., Giani, A., Capri, G., Viganó, L., Lacatelli, A., Bonadonna, G., & Egorin, M. J. (1995) · Journal of Clinical Oncology · doi:10.1200/jco.1995.13.1.180 · Cited by 553
Phase I study of recombinant tumor necrosis factor in cancer patients.
Blick, M. B., Sherwin, S. A., Rosenblum, M. G., & Gutterman, J. U. (1987) · PubMed · Cited by 426
Research works printed but not linked: 3
- D. Z. D'Argenio and A. Schumitzky. ADAPT II user's guide. Biomedical Simulations Resource, Los Angeles (1997).
- W. J. Jusko. Guidelines for collection and analysis of pharmacokinetic data. In W. E. Evans, J. J. Schentag, and W. J. Jusko (eds.), Applied Pharmacokinetics, Applied Therapeutics, Inc., Vancouver, 1992, Ch. 2.
- J. G. Wagner. A new generalized nonlinear pharmacokinetic model and its implications. In J. G. Wagner (ed.), Biopharmaceutics and Relevant Pharmacokinetics, Drug Intelligence Publications, Hamilton, 1971, pp. 302–317.
Cited by
Items 501–600 of 612
Formulation and Validation of an Extended Sigmoid Emax Model in Pharmacodynamics
Byun, J. H. (2024) · Pharmaceutical Research · doi:10.1007/s11095-024-03752-9 · Cited by 2
Bulitta, J. B., & Holford, N. H. G. (2014) · Wiley eBooks · doi:10.1002/9781118596333.ch27 · Cited by 2
Christensen, I. V., Loftager, M., Rode, F., Nielsen, H. M., Kreilgaard, M., & Larsen, M. S. (2019) · Journal of Thrombosis and Haemostasis · doi:10.1111/jth.14441 · Cited by 2
Proof-of-concept study on improved efficacy of rHuEPO administered as a long-term infusion in rats
Szczesny, D., Mołoniewicz, K., Markuszewski, M. J., & Wiczling, P. (2020) · Pharmacological Reports · doi:10.1007/s43440-020-00150-x · Cited by 2
Salgado, E., & Cao, Y. (2022) · Antibodies · doi:10.3390/antib11020028 · Cited by 2
Li, X., Dosne, A., Pérez‐Ruixo, C., & Ruixo, J. J. P. (2023) · Clinical Pharmacokinetics · doi:10.1007/s40262-023-01232-8 · Cited by 3
Pegram, P. S. (2015) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2015-eular.1472 · Cited by 2
Gibiansky, L. V., & Gibiansky, E. (2017) · Journal of Pharmacokinetics and Pharmacodynamics · doi:10.1007/s10928-017-9546-9 · Cited by 1
Shoji, S., Suzuki, A., Nouri, P., Cai, C., Gaitonde, P., & Marshall, S. F. (2023) · CPT Pharmacometrics & Systems Pharmacology · doi:10.1002/psp4.13015 · Cited by 1
Nipocalimab Dose Selection in Generalized Myasthenia Gravis
Valenzuela, B., Neyens, M., Zhu, Y., Ramchandren, S., Dosne, A., Leu, J. H., Faelens, R., Ling, L. E., & Pérez‐Ruixo, J. (2025) · CPT Pharmacometrics & Systems Pharmacology · doi:10.1002/psp4.70109 · Cited by 1
Hoyer-Kimura, C. H., Konhilas, J. P., & Hay, M. (2025) · Toxicology Reports · doi:10.1016/j.toxrep.2025.102151 · Cited by 1
Xu, M., Yuan, X., Li, P., Bach, T., Hao-Jie, Z., & An, G. (2026) · The AAPS Journal · doi:10.1208/s12248-025-01182-y · Cited by 1
Kim, T., Cha, J., Jeon, H., Yun, H., Lim, D., & Kim, J. K. (2026) · Computational and Structural Biotechnology Journal · doi:10.34133/csbj.0223 · Cited by 1
Tang, H., McCoy, M., Leonard, A., Mohan, K., Sane, R., Guan, C., Kullolli, M., & Koep, K. (2026) · The AAPS Journal · doi:10.1208/s12248-026-01216-z · Cited by 1
Song, S., Kim, J., Kim, S., Shin, B. S., & Shin, S. (2026) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2026.119345 · Cited by 2
Lopez, M. R., Román, M.-T. Á., Suarez, M. C., Vázquez, R. N., & López, C. A. (2026) · Haemophilia · doi:10.1111/hae.70285 · Cited by 1
Port, R. E., Boswell, C. A., Ogasawara, A. K., Gill, H. S., Mařík, J., Tarantal, A. F., Berg, E., Williams, S. P., & Ferl, G. Z. (2026) · Journal of Pharmacokinetics and Pharmacodynamics · doi:10.1007/s10928-026-10029-8 · Cited by 1
Rasool, B. K. A., Ali, I. S. M., & Shahiwala, A. (2026) · Journal of Pharmaceutical Analysis · doi:10.1016/j.jpha.2026.101701 · Cited by 1
Ligand‐Binding Assays to Support Disposition Studies of Macromolecular Therapeutics
Kelley, M. M., Mohler, M. A., & Findlay, J. W. A. (2009) · Wiley eBooks · doi:10.1002/9780470541517.ch2 · Cited by 1
Fakultät, M.-N.-T. (2005) · Cited by 1
Gibiansky, L. V., & Gibiansky, E. (2014) · Cited by 1
Biothérapies par voie sous-cutanée : modalités d’absorption et implications cliniques
Pinguet, F., & Milano, G. A. (2014) · ONCOLOGIE · doi:10.1007/s10269-014-2445-4 · Cited by 1
Gibiansky, L. V., & Gibiansky, E. (2019) · Wiley eBooks · doi:10.1002/9781119289234.ch7 · Cited by 1
Biomedical Research Regulation Challenges in Countries in Transition: Georgian Experience
Mulkijanyan, K., Chitiashvili, L., Ramishvili, M., & Megrelishvili, N. (2021) · European Scientific Journal ESJ · doi:10.19044/esj.2021.v17n18p41 · Cited by 1
Biotherapeutics ADME and PK/PD Principles
Yadav, D. B., Gadkar, K. G., & Figueroa, I. (2021) · Elsevier eBooks · doi:10.1016/b978-0-12-821044-4.00009-1 · Cited by 2
Byun, J. H., & Jung, I. H. (2021) · Applied Mathematical Modelling · doi:10.1016/j.apm.2021.12.032 · Cited by 1
Peters, S. A. (2021) · Wiley eBooks · doi:10.1002/9781119497813.ch13 · Cited by 1
Pharmacogenetic Biomarkers of Protein Therapeutics
Swaminathan, P. (2023) · Springer eBooks · doi:10.1007/978-981-19-8249-1_8 · Cited by 1
Mager, D. E., & Straubinger, R. M. (2023) · Journal of Pharmaceutical Sciences · doi:10.1016/j.xphs.2023.09.019 · Cited by 1
Self-citationRole of Statistical Physics Formalism in Pharmaceutical Science
Salman, S., Shah, F. H., & Kim, S. J. (2023) · Letters in Drug Design & Discovery · doi:10.2174/0115701808265088230922110240 · Cited by 1
Nguyen, V. A., Zhang, L., Kagan, L., Rowland, M., & Mager, D. E. (2023) · Journal of Pharmaceutical Sciences · doi:10.1016/j.xphs.2023.10.025 · Cited by 1
Self-citationGibiansky, L. V., Ng, C. M., & Gibiansky, E. (2024) · Journal of Pharmacokinetics and Pharmacodynamics · doi:10.1007/s10928-024-09917-8 · Cited by 1
Note on importance of correct stoichiometric assumptions for modeling of monoclonal antibodies
Gibiansky, L. V., & Gibiansky, E. (2024) · Journal of Pharmacokinetics and Pharmacodynamics · doi:10.1007/s10928-024-09918-7 · Cited by 1
Almholt, K., Wang, J., Pass, J., Røder, G., Padkjær, S. B., Hebsgaard, J. B., Xia, W., Yang, L., Forsell, J., Breinholt, V. M., et al. (2020) · Journal of Molecular Medicine · doi:10.1007/s00109-020-01889-9 · Cited by 1
Therapeutic antibody development—Remington chapter
Geist, B. J., Zheng, S., & Xu, Y. (2020) · Elsevier eBooks · doi:10.1016/b978-0-12-820007-0.00024-6 · Cited by 1
Cellular Trafficking of Monoclonal and Bispecific Antibodies
Rhoden, J. J., & Wiethoff, C. M. (2021) · Methods in pharmacology and toxicology · doi:10.1007/978-1-0716-1250-7_12 · Cited by 1
Zheng, S., Wang, W., & Zhou, H. (2015) · Wiley eBooks · doi:10.1002/9780470571224.pse545 · Cited by 3
Challenges in the Pharmacokinetics of Therapeutic Proteins
Limothai, W. (2015) · doi:10.21007/etd.cghs.2015.0184 · Cited by 1
Optimization of anemia management in preterm infants
Rosebraugh, M. (2012) · doi:10.17077/etd.hwpsy56k
Numeryczne modelowanie leczenia przeciwzakrzepowego
Beňová, M., & Gombárska, D. (2013) · PRZEGLĄD ELEKTROTECHNICZNY
Drug Development Strategies for Therapeutic Biologics: Industry Perspectives
Yuraszeck, T. M., & Gibbs, M. A. (2015) · Wiley eBooks · doi:10.1002/9780470571224.pse559
Wang, W., & Prueksaritanont, T. (2015) · Wiley eBooks · doi:10.1002/9780470571224.pse536
Process engineering of liver cells for drug testing applications
Tostões, R. M. (2012) · Portuguese National Funding Agency for Science, Research and Technology (RCAAP Project by FCT)
Modeling drug-protein dynamics
Peletier, L. A. (2011) · Discrete and Continuous Dynamical Systems - S · doi:10.3934/dcdss.2012.5.191
Therapeutic Monoclonal Antibodies and Their Targets
Figueroa, J. A., Peña, C., Mirandola, L., Reidy, A., Payne, J. D., Hosiriluck, N., Suvorava, N., Rahman, R. L., Whitlow, A. R., Verma, R., et al. (2016) · Wiley eBooks · doi:10.1002/9781118940648.ch4
Ait‐Oudhia, S., Lien, Y. T., Basu, S., Lesko, L. J., & Schmidt, S. (2019) · Wiley eBooks · doi:10.1002/9781119289234.ch10
Pharmacokinetic and pharmacodynamic modeling of drug absorption and delivery
Yan, X., & Kimko, H. H. C. (2013) · doi:10.4155/ebo.13.284
Wilkins, J. J. (2020) · Journal of Pharmacokinetics and Pharmacodynamics · doi:10.1007/s10928-020-09672-6
The role of quantitative modeling and simulation in translational science
Reddy, V. P., & Zhu, A. (2020) · Elsevier eBooks · doi:10.1016/b978-0-12-820018-6.00023-5
Tomaru, A., Toshimoto, K., Lee, W., Ishigame, K., & Sugiyama, Y. (2020) · Journal of Pharmaceutical Sciences · doi:10.1016/j.xphs.2020.10.050
[The problem of the prevention of pathologic suicide].
Pirozyński, T., Scripcaru, G., Gottlieb, H. J., Pirozyński, M., & Liciu, V. (1965) · PubMed
Physiologically Based Pharmacokinetic Modeling of Monoclonal Antibodies in Children
Malik, P. R. V. (2021) · UWSpace (University of Waterloo)
Bittner, B., & Schmidt, J. (2022) · Elsevier eBooks · doi:10.1016/b978-0-12-823741-0.00005-1
Mager, D. E., & Ramanathan, M. K. (2010) · Wiley eBooks · doi:10.1002/9780470571224.pse297
Self-citationSystem Analysis of Target-Mediated Drug Disposition (TMDD) Models
Radisavljević-Gajić, V. (2022) · IFAC-PapersOnLine · doi:10.1016/j.ifacol.2023.01.018
Naoi, S., Yamane, M., Nemoto, T., Kato, M., Saito, R., & Tachibana, T. (2023) · Drug Metabolism and Pharmacokinetics · doi:10.1016/j.dmpk.2023.100506
Huang, X., Xiang, H., Yang, S. C., Ye, L., Yang, X., Cui, C., Wu, Q., Wang, W., Huang, J., & Yang, G. (2024) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2024.2443756
Chen, E. P. (2025) · Wiley eBooks · doi:10.1002/9781119650263.ch11
PKPD modeling and in silico models
Pehrson, R., Winiwarter, S., Subramanian, V., Mogemark, M., & Miljković, F. N. (2025) · Elsevier eBooks · doi:10.1016/b978-0-443-29808-0.00022-4
Stability and Hopf Bifurcation of a Target-Mediated Drug Disposition Model
Zhao, T., Li, X., Su, L., & Yan, Y. (2025) · Journal of Applied Mathematics and Physics · doi:10.4236/jamp.2025.1312235
Daix, T., Mathonnet, A., Brakenridge, S. C., Dequin, P.-F., Mira, J. P., Berbille, F., Morre, M., Jeannet, R., Blood, T., Unsinger, J., et al. (2024) · Figshare · doi:10.6084/m9.figshare.26574649
Daix, T., Mathonnet, A., Brakenridge, S. C., Dequin, P.-F., Mira, J. P., Berbille, F., Morre, M., Jeannet, R., Blood, T., Unsinger, J., et al. (2024) · Figshare · doi:10.6084/m9.figshare.26574652
Ghazal, H., Leuchter, S., Ngo, R., Kinzel, M., Dabas, R., Dharmani‐Khan, P., Khan, F. M., Jamani, K., Li, N., Kiang, T. K. L., et al. (2026) · Transplantation and Cellular Therapy · doi:10.1016/j.jtct.2026.01.005
Real world data based evaluation of a novel target-mediated drug disposition approximation modelPreprint
Jeon, H., Jung, W., Yun, H., Lee, S., Kim, J. K., Chae, J., & Byun, J. H. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.01.20.700502
Analysis and Simulation of Some Target-Mediated Drug Disposition Mathematical Models
Radisavljević-Gajić, V., & Alaleeli, A. (2025) · International Conference on Electrical and Computer Engineering Researches (ICECER) · doi:10.1109/icecer65523.2025.11401370
Li, M., Li, Y., Zeng, S., Wang, Y., Ji, Y., Yang, G.-P., & Tang, J. (2026) · European Journal of Drug Metabolism and Pharmacokinetics · doi:10.1007/s13318-026-00987-2
Elalem, A., Ette, M. E., & Mager, D. E. (2026) · Pharmaceutical Research · doi:10.1007/s11095-026-04044-0
Self-citationPointreau, Y. (2015) · theses.fr (ABES) · doi:10.70675/91e6dfa3z6265z49e8zb154zfb77a343430f · Cited by 1
Elimination des anticorps monoclonaux par leur cible : étude par modélisation pharmacocinétique
Tilly, O. L. (2022) · theses.fr (ABES) · doi:10.70675/41dc2382z5d5dz49efz80dcza3bd9bb0b6ac
Oumghar, I. A. (2023) · theses.fr (ABES) · doi:10.70675/0ae9ddeazcedfz47c7zb864z797d6395c6fb
Physiologically based pharmacokinetics of dexamethasone in rats featuring nonlinear tissue binding
Wu, W., Yanamandala, N., & Jusko, W. J. (2026) · Drug Metabolism and Disposition · doi:10.1016/j.dmd.2026.100328
Self-citationTopological Pharmacokinetics: Reading the Shape of Drug Disposition from DataPreprint
Ren, H., & Gu, Y.-X. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.05.13.724751
Nayak, R. A. K., Sharma, N., Tripathi, D., Mishra, A., Maurya, A., & Singh, A. K. (2026) · International Journal of Drug Delivery Technology · doi:10.25258/ijddt.16.44s.102
Liu, J.-L., Liu, Y.-X., Zhang, X.-J., Wang, G.-L., Huang, J., Zhang, H.-F., Xu, N., Zhang, S.-N., Yue, X., Liang, X.-X., et al. (2026) · International Journal of Pharmaceutics X · doi:10.1016/j.ijpx.2026.100586 · Cited by 1
Burlot, C., Riglet, F., Romagnoli, M., Leconte, A., Delmas, A., Schmitt, A., & Fouliard, S. (2026) · CPT Pharmacometrics & Systems Pharmacology · doi:10.1002/psp4.70288
Niazi, S. K. (2026) · Frontiers in Drug Discovery · doi:10.3389/fddsv.2026.1799663
A simple algebraic expression can determine if a drug’s clearance is non-specific or target-mediated
Brown, L., Ippolito, A., Penney, M., & Jones, R. D. (2026) · Journal of Pharmacokinetics and Pharmacodynamics · doi:10.1007/s10928-026-10043-w
Calculating Receptor Occupancy using TMDD Models – What has to be Considered?
Fu, Y., Yang, L., Su, H., Yao, Y., Li, Y., & Ma, P. (2026) · The AAPS Journal · doi:10.1208/s12248-026-01269-0
Yuan, X., Thalhauser, C. J., Afzal, N., Kemper, K., An, G., & Li, T. R. (2026) · The AAPS Journal · doi:10.1208/s12248-026-01259-2
Rahman, E., Rao, P., Ahmed, M., Saklayen, G., Ahmed, I., Khan, M. S., Joseph, J. H., & Webb, W. R. (2026) · Toxicon · doi:10.1016/j.toxicon.2026.109250
Kumar, D., Verma, A., & Trivedi, N. (2026) · Biochemical Pharmacology · doi:10.1016/j.bcp.2026.118364
Decoding Hepatitis Therapeutics
Sahu, P., Dikhit, M. R., Tiwari, P., & Sahoo, R. (2026) · Wiley eBooks · doi:10.1002/9781394466573.ch12
Zhang, Y., Wang, H., Furukawa, N., Patil, A., Arulraj, T., & Popel, A. S. (2026) · ACS Pharmacology & Translational Science · doi:10.1021/acsptsci.6c00347
When medicine repays physics: A pharmacokinetic toolkit for chaotic three-body scattering
Onishi, T. (2026) · Chaos Solitons & Fractals · doi:10.1016/j.chaos.2026.119159
Quantitative Model of the Ocular Immune Response during Seasonal Allergic ConjunctivitisPreprint
Gunputh, N. D., Maki, K. L., Carichino, L., & Woeller, C. F. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.09.21.753366
Exposure–Response Analyses of Ropeginterferon Alfa‐2b in Essential Thrombocythemia
Qin, A., Masárová, L., Chen, H., Xiao, Z., Jie, J., Gill, H., Reeves, B., Chaer, F. E., Kirito, K., Komatsu, N., et al. (2026) · The Journal of Clinical Pharmacology · doi:10.1002/jcph.70258
del Amo, E. M., Sanjuan, V. M., & Fernández‐Ferreiro, A. (2026) · Eye · doi:10.1038/s41433-026-04922-2
Cuquerella-Gilabert, M., Martín‐Sabroso, C., Zarzoso-Foj, J., Aparicio-Blanco, J., Balsa, A., Torres‐Suárez, A. I., Sanjuan, V. M., & Rodríguez‐Nogales, C. (2026) · Frontiers in Pharmacology · doi:10.3389/fphar.2026.1917187
Byun, J. H., Park, I., Yun, H., & Kim, J. K. (2026) · Computational and Structural Biotechnology Journal · doi:10.34133/csbj.0248
Chen, H., & Liang, S. (2026) · Frontiers in Pharmacology · doi:10.3389/fphar.2026.1951110
Metadata
- Authors
- Mager, D. E., & Jusko, W. J.
- Affiliations
- University at Buffalo, State University of New York (US)
- Venue
- Journal of Pharmacokinetics and Pharmacodynamics
- Published
- 2001-12
- Volume
- 28
- Issue
- 6
- Pages
- 507-532
- ISSN
- 1567-567X (ISSN-L)
- 1573-8744
- OpenAlex
- W28215347
- Cited by
- 605
- References
- 40
- Citations by year
- 2026: 40 · 2025: 27 · 2024: 30 · 2023: 32 · 2022: 31 · 2021: 31 · 2020: 40 · 2019: 37 · 2018: 28 · 2017: 31 · 2016: 32 · 2015: 41 · 2014: 31 · 2013: 36 · 2012: 32
- FWCI
- 2.98
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springernature.com/gp/researchers/text-and-data-mining (tdm)
- www.springernature.com/gp/researchers/text-and-data-mining (vor)
- Locations
- Journal of Pharmacokinetics and Pharmacodynamics (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Institute of General Medical Sciences (GM 57980, R01GM057980)
- Topics
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmacology › Pharmacogenetics and Drug Metabolism
- Physical Sciences › Mathematics › Statistics and Probability › Statistical Methods in Clinical Trials
- Health Sciences › Medicine › Pediatrics, Perinatology and Child Health › Pharmaceutical studies and practices
- Keywords
- target-mediated drug disposition, nonlinear pharmacokinetics, receptor-mediated endocytosis, pharmacokinetic modeling, dose-dependent clearance, drug elimination, bosentan, interferon beta-1a, enzyme inhibitors, receptor antagonists
- MeSH terms
- Bosentan, Dose-Response Relationship, Drug, Drug Evaluation, Preclinical, Fluorenes, Humans, Hydantoins, Male, Models, Chemical, Pharmacokinetics, Sulfonamides, Drug Delivery Systems, Interferon-beta, Nonlinear Dynamics
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.